Using 64Cu-DOTATATE PETCT Imaging to Diagnose Cardiac Sarcoidosis and Related Heart Inflammations

What this Trial Is About

This research aims to evaluate the diagnostic value of activated macrophage imaging in patients with or being evaluated for cardiac sarcoidosis using the PETCT tracer 64Cu-DOTATATE. Cardiac sarcoidosis is a serious condition often causing death in affected patients, and current imaging methods like 18F-FDG PETCT have limitations due to high uptake in normal heart muscle and require extensive patient preparation. The study seeks to find a tracer with better sensitivity and specificity that does not require such preparation or carry the same risks. Participants are divided into four groups those with suspected cardiac sarcoidosis, those with confirmed cardiac sarcoidosis, those with suspected or confirmed acute lymphocytic myocarditis, and a control group of patients with neuroendocrine tumors who have previously undergone 64Cu-DOTATATE PETCT scans. Groups A and B will receive both 64Cu-DOTATATE and 18F-FDG PETCT scans, group C will have only the 64Cu-DOTATATE scan, and group Ds existing scan data will be included retrospectively. During the study, participants will undergo PETCT scans to measure tracer uptake, which will help distinguish activated macrophages in the heart. Researchers will monitor and record tracer distribution and adverse outcomes over two years. The study includes clinical and imaging assessments to understand the patterns of inflammation in cardiac sarcoidosis and related conditions. Total participation time involves the scanning procedures and follow-up assessments over 24 months.

Macrophage PET/CT Imaging Using 64Cu-DOTATATE for the Diagnosis of Cardiac Sarcoidosis